ARF the integrator: Linking NF-κB, p53 and checkpoint kinases

Cell Cycle

Volumn 4, Issue 6, 2005, Pages 756-759

  Rocha, Sonia ^a   Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

ATM; ATR; Checkpoint kinase; Chk1; NF b; Nucleolus; p14ARF; p53; p65; RelA

Indexed keywords

ARF PROTEIN; CHECKPOINT KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; PROTEIN SUBUNIT; THREONINE;

APOPTOSIS; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; EXPERIMENTAL MOUSE; GENE ACTIVATION; GENE EXPRESSION; MITOSIS INHIBITION; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 25144473970     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.6.1739     Document Type: Review

References (32)

1. Vousden KH. Activation of the p53 tumor suppressor protein. BBA - Rev Cancer 2002; 1602:47-59.
2. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002; 12:53-9.
3. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004; 18:2195-224.
4. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309.
5. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by ReIA(p65) NF-κB. Mol Cell 2004; 13:853-65.
6. Hiscott J, Kwon H, Genin P. Hostile takeovers: Viral appropriation of the NF-κB pathway. J Clin Invest 2001; 107:143-51.
7. Lin A, Karin M. NF-κB in cancer: A marked target. Semin Cancer Biol 2003; 13:107-114.
8. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001; 107:241-6.
9. Kucharczak J, Simmons MJ, Fan YJ, Gelinas C. To be, or not to be: NF-κB is the answer - role of Rel/NF- κB in the regulation of apoptosis. Oncogene 2003; 22:8961-82.
10. Perkins ND. NF-κB: Tumor promoter or suppressor? Trends Cell Biol 2004; 14:64-9.
11. Campbell KJ, Perkins ND. Reprogramming RelA. Cell Cycle 2004; 3:869-72.
12. Sherr CJ. An Arf (GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo. Cell Cycle 2004; 3:239-40.
13. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 2003; 13:77-83.
14. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2:731-7.
15. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25.
16. Gallagher S, Kefford RF, Rizos H. Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis. Cell Cycle 2005; 4:465-72.
17. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-96.
18. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 2005; 24:1157-69.
19. Hutchins JRA, Hughes M, Clarke PR. Substrate specificity determinants of the checkpoint protein kinase Chk1. Febs Letters 2000; 466:91-5.
20. Llanos S, Clark PA, Rowe J, Peters G. Stabilization of p53 by p14(ARF) without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001; 3:445-52.
21. Rodway H, Llanos S, Rowe J, Peters G. Stability of nucleolar versus nonnucleolar forms of human p14(ARF). Oncogene 2004; 23:6186-92.
22. Foray N, Marot D, Gabriel A, Randrianarison V, Carr AM, Perricaudet M, Ashworth A, Jeggo P. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J 2003; 22:2860-71.
23. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 2004; 14:11-10.
24. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 2003; 300:1542-8.
25. Li Y, Wu D, Chen B, Ingram A, He L, Liu L, Zhu D, Kapoor A, Tang D. ATM activity contributes to the tumor-suppressing functions of p14(ARF). Oncogene 2004; 23:7355-65.
26. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-κB and IκB proteins: Implications in cancer and inflammation. Trends Biochem Sci 2005; 30:43-52.
27. Campbell KJ, Perkins ND. Post-translational modification of RelA(p65) NF-κB. Biochem Soc Trans 2004; 32:1087-9.
28. Vousden K. Regulation and function of the p53 tumour suppressor protein. Br J Cancer 2003; 88:S7.
29. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999; 96:14973-7.
30. de Toledo SM, Azzam EI, Dahlberg WK, Gooding TB, Little JB. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene 2000; 19:6185-93.
31. Shinozaki T, Nota A, Taya Y, Okamoto K. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene 2003; 22:8870-80.
32. Maya R, Balass M, Kim ST, Shkedy D, Leal JFM, Shifman O, Moas M, Buschmann T, Ronai Z, Shiloh Y, Kastan MB, Katzir E, Oren M. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev 2001; 15:1067-77.